WASHINGTON — Almost no one is prescribing Aduhelm, the controversial new Alzheimer’s treatment that roiled the health care landscape when regulators approved it this summer.
Major health care systems like the Cleveland Clinic made it clear almost immediately that they wouldn’t offer the new therapy, citing a lack of convincing evidence that the drug actually helps treat Alzheimer’s disease. Now, STAT has identified another 15 university-affiliated hospitals that aren’t offering the drug, including Johns Hopkins, University of California Los Angeles, and the University of Michigan.
The organization that negotiates supply contracts on behalf of more than 95% of the nation’s academic hospitals estimates their members are ordering just one to five vials of the medicine each day.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect